Results 51 to 60 of about 11,153 (206)

Dopamine D2 Receptor Agonists as Modulators of VEGF‐A‐Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Interplay between VEGF‐A‐driven angiogenesis and DRD2‐mediated inhibition. Tumor‐derived VEGF‐A activates VEGFR2 on endothelial cells, triggering proangiogenic signaling pathways that promote abnormal vessel growth and vascular leakage. VEGF‐A also induces DRD2 expression, establishing a feedback mechanism.
Venu Akkanapally, Aman Kumar, Inemai Ezhil, Manas Ranjan Sahu, Xue‐Feng Bai, Kamal S. Pohar, Sujit Basu   +6 more
wiley   +1 more source

Effects of Bromocriptine on Dopamine Turnover with or without Levodopa

, 1996
Bromocriptine, a dopamine agonist, alleviates symptoms of Parkinson's disease, even when administered alone, and is used for its treatment. Better therapeutic effects are, however, achieved when bromocriptine is used in combination with levodopa.
M Asanvma, K Matsuura, K Iida, M Yamamoto, K Tanaka, N Ogawa   +5 more
core   +1 more source

Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes

Molecular Metabolism, 2021
Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous system actions.
G. Tavares, D. Marques, C. Barra, D. Rosendo-Silva, A. Costa, T. Rodrigues, P. Gasparini, B.F. Melo, J.F. Sacramento, R. Seiça, S.V. Conde, P. Matafome   +11 more
doaj   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, Volume 183, Issue 10, Page 2518-2532, May 2026.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Reversible cerebral vasoconstriction syndrome: A narrative review

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1162-1180, May 2026.
Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa, Abner da Silva Machado, Arthur de Oliveira Veras, Thiago Oscar Goulart, Sarah Galassi Tatsuta, Trajano Aguiar Pires Gonçalves, Eva Rocha, Octávio Marques Pontes‐Neto   +7 more
wiley   +1 more source

Central Hyperthermia Treated with Bromocriptine

, 2017
Introduction. Central hyperthermia is common in patients with brain injury. It typically has a rapid onset with high temperatures and marked fluctuations and responds poorly to antibiotics and antipyretics.
P. Nattanmai, R. Bell, P. Natteru, P. George, C. R. Newey   +4 more
core   +1 more source

DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut

Advanced Science, Volume 13, Issue 24, 27 April 2026.
Dopamine receptor D2 (DRD2) deficiency disrupts epithelial barrier integrity in both the gut and pituitary gland, facilitating translocation of gut‐derived Escherichia coli into pituitary tissue. Intratumoral E. coli are phagocytosed by microglia, triggering GSDMD‐dependent pyroptosis and HMGB1 release, which subsequently activates MAPK signaling to ...
Xian‐jun Su, Li Ma, Xi Xiong, Jun‐hua Meng, Qi Wu, Yu Zhang, Shu‐guang Dong, Yue‐fei Wang, Jin‐hu Wu, Qing‐yuan Zeng, Hong‐feng Zhang, Li‐li Li, Liang Meng, Min Peng, Xiao‐dong Huang, Li‐quan Wu, Xiong Wang   +16 more
wiley   +1 more source

Bromocriptine for idiopathic oligo/asthenospermia.

, 2000
Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology)of unknown cause is common and the need for treatment is felt by patients and doctors alike.
Vail, A.; id_orcid, Vandekerckhove, P., Lilford, R., Hughes, E.   +3 more
core   +1 more source

Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review

Acta Medica Indonesiana, 2023
Breast cancer is among the deadliest gynecology cancers in the world. However, the management of advanced-stage breast cancer is often harder as a result of chemoresistance.
Muhammad Yadi Permana, Sarwanti Sarwanti, Siti Fauziah   +2 more
doaj   +2 more sources

Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia [PDF]

Journal of Clinical and Diagnostic Research, 2013
Introduction: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like ...
Harish Kumar V.S., Vinutha M.B., Pradeep A.N., Sathisha Aithal, Sindhura Reddy Baleed, Umakant N. Patil   +5 more
doaj   +1 more source